Modality
Cell Therapy
MOA
KRASG12Di
Target
DLL3
Pathway
RNA Splicing
CMLFL
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Aug 2028
Phase 1Current
NCT05618377
205 pts·FL
2017-09→2028-08·Not yet recruiting
NCT04703881
1,171 pts·FL
2024-08→TBD·Terminated
1,376 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-012.3y awayInterim· FL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
P1
Termina…
Catalysts
Interim
2028-08-01 · 2.3y away
FL
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05618377 | Phase 1 | FL | Not yet recr... | 205 | eGFR |
| NCT04703881 | Phase 1 | FL | Terminated | 1171 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |